Amphion Innovations plc

Further Investment in Polarean Imaging plc
and Repayment of Loan Facility

London and New York, 11 December 2018 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, notes that its partner company Polarean Imaging plc ("Polarean") has announced a conditional fundraise of US$4.0 million (£3.125 million) (before expenses) by the issue of, in aggregate, 22,321,429 ordinary shares of £0.00037 each in the capital of the company with new and existing investors at a price of 14p per share (“the Placing”). The Placing is conditional on admission of the new Polarean shares to trading on AIM (“Admission”) which is expected to occur on or around 28 December 2018.  Amphion has participated in the Placing and following Admission, will remain the largest shareholder, holding approximately 18.4 million shares, equivalent to 18.2% of the enlarged Share Capital of Polarean.

In addition to the investment in Polarean, Amphion has made a payment of US $304,377 to reduce the loan balance under the facility announced on 5 June 2014 (the "Facility"). After the payment, the loan balance will be US$3,984,256 As announced in the Company’s announcement dated 16 October 2018, the Company has committed to maintain a certain value of the pledged Motif Bio plc shares compared to the outstanding balance of the Facility and this payment was made pursuant to those terms. In the future, should the value of the pledged shares not meet the terms, the Board may be required to make additional payments or renegotiate the Facility. It is the Board’s intention to make any repayments in cash. The loan balance plus accrued interest will be due on 30 September 2019.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

For further information please contact

Amphion Innovations
Charlie Morgan
+1 212 210 6224

Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Emma Earl / Ryan McCarthy (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500

Northland Capital Partners Limited (Joint Corporate Broker)
David Hignell (Corporate Finance)
Rob Rees (Corporate Broking)
+44 (0)20 3861 6600

Walbrook PR
Anna Dunphy / Paul McManus
+44 (0)20 7933 8780

About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.